down arrow

Prime Medicine, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74168J1016
USD
4.43
-0.25 (-5.24%)

Jan 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.344.66

52 Week

1.116.94
Valuation
Technical
Day's Volume

CASH

2.25 M

Shareholding (Sep 2025)

FII

6.12%

Held by 46 FIIs

DII

63.43%

Held by 25 DIIs

Promoter

13.56%

How big is Prime Medicine, Inc.?

22-Jun-2025

As of Jun 18, Prime Medicine, Inc. has a market capitalization of 212.04 million, with net sales of 3.84 million and a net profit of -202.02 million over the last four quarters. Shareholder's funds are 153.15 million, and total assets are 490.14 million.

As of Jun 18, Prime Medicine, Inc. has a market capitalization of 212.04 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 3.84 million, while the sum of net profit for the same period is -202.02 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 153.15 million, and total assets are reported at 490.14 million.

View full answer

What does Prime Medicine, Inc. do?

22-Jun-2025

Prime Medicine, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $52 million as of March 2025. It has a market cap of $212.04 million and key metrics indicating significant financial challenges.

Overview:<BR>Prime Medicine, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -52 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 212.04 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.29 <BR>Return on Equity: -186.40% <BR>Price to Book: 1.98<BR><BR>Contact Details:<BR>Registrar Address: Not available.

View full answer

Is Prime Medicine, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Prime Medicine, Inc. shows a mildly bullish trend with mixed technical indicators, including bullish moving averages and MACD, but bearish RSI readings, while outperforming the S&P 500 significantly over the past month and year-to-date.

As of 10 October 2025, the technical trend for Prime Medicine, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the RSI readings are bearish for both weekly and monthly periods. The Bollinger Bands indicate a mildly bullish stance weekly and bullish monthly. Moving averages are bullish on a daily basis, while the Dow Theory shows a mildly bullish trend in both weekly and monthly time frames. The OBV is mildly bullish weekly but mildly bearish monthly. <BR><BR>In terms of performance, the stock has returned 38.82% over the past month compared to a mere 0.31% for the S&P 500, and it has a year-to-date return of 93.49% against the S&P 500's 11.41%. Overall, the current technical stance is mildly bullish, driven by the mixed indicators across different time frames.

View full answer

Compare Prime Medicine, Inc. with Similar Stocks

Immatics NVRayzebio, Inc.Replimune Group, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Positive results in Jun 25

  • NET SALES(HY) At USD 2.57 MM has Grown at 334.69%
  • OPERATING CASH FLOW(Y) Highest at USD -99.94 MM
  • NET PROFIT(HY) Higher at USD -102.92 MM
2

Risky - Negative EBITDA

3

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 692 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.27

stock-summary
Return on Equity

-121.92%

stock-summary
Price to Book

4.27

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Sep 2025)
Net Profit:
-51 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.66%
0%
-17.66%
6 Months
-4.53%
0%
-4.53%
1 Year
35.89%
0%
35.89%
2 Years
-32.98%
0%
-32.98%
3 Years
-73.54%
0%
-73.54%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Prime Medicine, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Prime Medicine Stock Hits Day Low of $4.45 Amid Price Pressure

Prime Medicine Stock Hits Day Low of $4.45 Amid Price Pressure

Prime Medicine, Inc. has faced a significant stock decline, with a notable drop in both weekly and monthly performance. Despite reporting substantial growth in net sales, the company struggles with negative EBITDA and high operating cash flow losses. Its long-term performance reflects considerable volatility in the market.

Read full news article

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
81.31%
EBIT Growth (5y)
-36.99%
EBIT to Interest (avg)
-162.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.29
Sales to Capital Employed (avg)
0.02
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
43.46%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.08
EV to EBIT
-0.41
EV to EBITDA
-0.42
EV to Capital Employed
-2.77
EV to Sales
21.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-186.40%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 33 Schemes (16.86%)

Foreign Institutions

Held by 46 Foreign Institutions (6.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 500.00% vs 0.00% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 3.62% vs -3.55% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.20",
          "val2": "0.20",
          "chgp": "500.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-52.10",
          "val2": "-52.70",
          "chgp": "1.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.50",
          "val2": "0.20",
          "chgp": "650.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-50.60",
          "val2": "-52.50",
          "chgp": "3.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-44,059.60%",
          "val2": "-259,483.30%",
          "chgp": "21,542.37%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.11% vs -62.64% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-196.30",
          "val2": "-186.60",
          "chgp": "-5.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-15.90",
          "chgp": "96.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-195.90",
          "val2": "-198.10",
          "chgp": "1.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-67,873.60%",
          "val2": "0.00%",
          "chgp": "-6,787.36%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoYstock-summary

Sep'25
Sep'24
Change(%)
Net Sales
1.20
0.20
500.00%
Operating Profit (PBDIT) excl Other Income
-52.10
-52.70
1.14%
Interest
0.00
0.00
Exceptional Items
1.50
0.20
650.00%
Consolidate Net Profit
-50.60
-52.50
3.62%
Operating Profit Margin (Excl OI)
-44,059.60%
-259,483.30%
21,542.37%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2025 is 500.00% vs 0.00% in Sep 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 3.62% vs -3.55% in Sep 2024

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
3.00
0.00
Operating Profit (PBDIT) excl Other Income
-196.30
-186.60
-5.20%
Interest
0.00
0.00
Exceptional Items
-0.50
-15.90
96.86%
Consolidate Net Profit
-195.90
-198.10
1.11%
Operating Profit Margin (Excl OI)
-67,873.60%
0.00%
-6,787.36%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1.11% vs -62.64% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Prime Medicine, Inc. stock-summary
stock-summary
Prime Medicine, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."